Form D · Biotechnology
Ivenix, Inc.
Amesbury, MA · CIK 0001402551
Offering snapshot reported Mar 17, 2017 · SEC filing
- Reported sold
- $10M Offering amount: $50M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 7, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 17, 2017 | Initial | $10,000,002 | No comparison | 18 | SEC filing |
| Sep 3, 2015 | Initial | $14,799,997 | No comparison | 43 | SEC filing |
| Sep 3, 2015 | Initial | $27,500,000 | No comparison | 25 | SEC filing |
| Aug 11, 2011 | Initial | $19,825,040 | No comparison | 19 | SEC filing |
| Feb 23, 2011 | Initial | $499,999 | No comparison | 5 | SEC filing |
| Oct 8, 2010 | Amendment | $10,272,451 | $0vs Oct 7, 2010 | 21 | SEC filing |
| Oct 7, 2010 | Amendment | $10,272,451 | $348,514vs Apr 5, 2010 | 21 | SEC filing |
| Apr 5, 2010 | Amendment | $9,923,937 | $840,577vs Mar 10, 2010 | 19 | SEC filing |
| Mar 10, 2010 | Initial | $9,083,360 | No comparison | 12 | SEC filing |
| Jul 31, 2009 | Initial | $2,301,309 | No comparison | 0 | SEC filing |
| Jun 5, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jun 5, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-282805
The total offering amount of $49,999,996 will be sold under three tranches. The first tranche equal to approximately 20% of the total offering amount was sold on March 7, 2017. The remaining two tranches will be sold upon the occurrence of certain events.
Source: Form D, filed Mar 17, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jesse Ambrosina | Executive |
| Thomas Bassinger | Director |
| Benjamin Bulkley | Director, Executive |
| Jeffrey Carlisle | Director, Executive |
| John Clarke | Director |
| Darrell J. Crate | Director |
| John Douglass | Director |
| Colin J. Foster | Director |
| George Gray | Executive |
| Charles Hadley | Director |
| Brandon Hull | Director |
| Lawrence Kuba | Executive |
| Wei Li | Director |
| Carolyn Malleck | Executive |
| Brent Nibarger | Executive |
| Ketan Patel | Director |
| Stuart Randle | Director, Executive |
| John Sokolowski | Executive |
| Christian Taubman | Executive |
| Wayne B. Weisman | Director |
| John Wu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
21 Water Street 4th Floor
Amesbury, MA, 01913
Amesbury, MA, 01913